Clinical Trials Logo

Solid Tumor, Adult clinical trials

View clinical trials related to Solid Tumor, Adult.

Filter by:

NCT ID: NCT03976050 Terminated - Solid Tumor, Adult Clinical Trials

Phase I Study of HL-085 in Patients With Advanced Solid Tumors

Start date: June 17, 2019
Phase: Phase 1
Study type: Interventional

The study drug, HL-085 is a MEK inhibitor with the potential indication for cancers. It is an oral medication to be given daily. The purposes of this study is to find answers to the following research questions: 1. What is the highest tolerable dose of HL-085 that can be given to subjects when given orally (by mouth) on a twice daily basis? 2. What are the side effects of HL-085? 3. How much HL-085 is in the blood at specific times after dosing and how does the body get rid of the HL-085?

NCT ID: NCT03951116 Completed - Solid Tumor, Adult Clinical Trials

Study of FCN-437c in Patients With Advanced Solid Tumors

FCN-437c
Start date: June 25, 2019
Phase: Phase 1
Study type: Interventional

This research study is studying a drug called FCN-437c as a possible treatment for patients with advanced unresectable/metastatic solid tumors.

NCT ID: NCT03941262 Completed - Clinical trials for Advanced Solid Tumor

Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy

Start date: July 15, 2019
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate the safety and preliminary efficacy of SNK01 (autologous natural killer cell), as a single agent and in combination with avelumab or pembrolizumab, for the treatment of subjects with advanced and/or metastatic refractory cancer that has failed three or more prior lines of conventional standard of care therapy.

NCT ID: NCT03929653 Enrolling by invitation - Solid Tumor, Adult Clinical Trials

Personalized Therapy of Molecular Tumor Board Participation With the Guidance of Next Generation Sequencing

Start date: June 1, 2017
Phase:
Study type: Observational

This study seeks to evaluate the clinical value of the personalized therapy model with the guidance of Molecular Tumor Board (MTB) after Next Generation Sequencing(NGS), and to track patient outcomes.

NCT ID: NCT03927599 Enrolling by invitation - Solid Tumor, Adult Clinical Trials

Advanced Refractory Solid Tumors With TP53 Mutations Register Study

Start date: August 1, 2018
Phase:
Study type: Observational

The efficacy and safety of the PARP inhibitor in combination with the VEGFR inhibitor will be investigated in advanced refractory solid tumors patients with TP53 mutation .

NCT ID: NCT03922204 Recruiting - Advanced Cancer Clinical Trials

A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies

Start date: May 8, 2019
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open label, non-randomised, dose-escalation single agent study with expansion cohorts for dose confirmation/safety and preliminary efficacy of MCLA-145 in advanced or metastatic malignancies

NCT ID: NCT03919292 Recruiting - Solid Tumor, Adult Clinical Trials

Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

Start date: May 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

To determine the recommended phase 2 dose (RP2D) of the combination of neratinib and sodium valproate when given to patients with advanced solid tumors. Then to explore the antitumor effects of the neratinib and sodium valproate combination in advanced solid tumors with attention to RAS-mutated tumors, EGFR-altered GBM, and ocular melanoma, as part of the phase 2 expansion cohort.

NCT ID: NCT03915678 Recruiting - Pancreatic Cancer Clinical Trials

Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

AGADIR
Start date: March 31, 2021
Phase: Phase 2
Study type: Interventional

Basket trial concept to independently and simultaneously assess the effects of the association of atezolizumab + BDB001 + radiotherapy in multiple solid tumors.

NCT ID: NCT03914872 No longer available - Solid Tumor, Adult Clinical Trials

Expanded Access Neoantigen Vaccine in Solid Tumors

Start date: n/a
Phase:
Study type: Expanded Access

This is an expanded access use study. Safety data will be collected from participants.

NCT ID: NCT03905148 Recruiting - Solid Tumor, Adult Clinical Trials

Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors

Start date: May 1, 2019
Phase: Phase 1
Study type: Interventional

This is a 2-part Phase 1b study of BGB-283 (lifirafenib) and PD-0325901 (mirdametinib) combination in participants with tumors.